Coherus Oncology (NASDAQ:CHRS) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of Coherus Oncology (NASDAQ:CHRS) in a report released on Thursday, Marketbeat.com reports. The brokerage issued a buy rating on the biotechnology company’s stock.

Separately, Weiss Ratings raised shares of Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, October 26th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Coherus Oncology presently has an average rating of “Moderate Buy” and an average price target of $11.00.

Coherus Oncology Stock Down 7.6%

NASDAQ:CHRS opened at $0.83 on Thursday. Coherus Oncology has a one year low of $0.81 and a one year high of $2.62. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.77 and a quick ratio of 1.70. The company has a market cap of $128.25 million, a PE ratio of -0.81 and a beta of 0.98. The firm’s 50 day simple moving average is $1.20 and its 200 day simple moving average is $1.53.

Coherus Oncology (NASDAQ:CHRS) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.06. The firm had revenue of $14.31 million during the quarter, compared to analysts’ expectations of $14.41 million. Coherus Oncology had a negative net margin of 259.41% and a negative return on equity of 222.75%. On average, research analysts anticipate that Coherus Oncology will post -0.88 earnings per share for the current year.

Hedge Funds Weigh In On Coherus Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in CHRS. Spark Investment Management LLC bought a new position in shares of Coherus Oncology in the second quarter valued at $25,000. Cetera Investment Advisers acquired a new position in shares of Coherus Oncology during the first quarter valued at about $54,000. Dimensional Fund Advisors LP acquired a new position in shares of Coherus Oncology during the first quarter valued at about $60,000. The Manufacturers Life Insurance Company bought a new stake in shares of Coherus Oncology during the second quarter worth about $54,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Coherus Oncology during the second quarter worth about $131,000. Institutional investors own 72.82% of the company’s stock.

Coherus Oncology News Roundup

Here are the key news stories impacting Coherus Oncology this week:

• Positive Sentiment: Early data for tagmokitug in esophageal squamous cell carcinoma were encouraging enough to support a broader study, strengthening the case for additional development of Coherus’s oncology pipeline. The results are a potential catalyst, although the program remains clinical-stage and further testing is required. Coherus Oncology stock: Tagmokitug data support broader study
• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating, signaling favorable analyst views on Coherus’s longer-term opportunity. Its forecasts call for improving results, including a projected return to positive EPS in 2030. HC Wainwright Initiates Coverage on Coherus Oncology
• Neutral Sentiment: HC Wainwright expects Coherus to remain unprofitable in the near term, forecasting EPS of negative $0.91 for fiscal 2026 and negative $0.63 for fiscal 2027. Losses are projected to narrow to negative $0.48 in 2028 and negative $0.19 in 2029 before reaching positive $0.19 in 2030.
• Negative Sentiment: The near-term earnings outlook remains weak, with estimated quarterly losses ranging from $0.13 to $0.22 per share through the covered periods. Continued negative earnings and reliance on successful clinical development may be weighing on sentiment despite the Buy rating and positive tagmokitug data.
• Negative Sentiment: Recent reporting characterized the tagmokitug results as promising but preliminary, leaving uncertainty over whether the therapy can expand into additional indications and ultimately produce commercial revenue. Early data good in ESCC, but can Coherus tagmo indications?

About Coherus Oncology

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.